# <p>Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer</p>

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/and-lt-p-and-gt-cost-effectiveness-analysis-of-ceritinib-and-alectinib-versus/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Maobai Liu,Longfeng Zhang,Qishu Huang,Na Li,Bin Zheng,Hongfu Cai |
| Citations | 22 |
| DOI | 10.2147/cmar.s223441 |
| Fields | Economics, Econometrics and Finance,Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://www.dovepress.com/getfile.php?fileID=53526 |
| OpenAlex ID | https://openalex.org/W2982045845 |
| PMID | 31749634 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Longfeng Zhang](https://scholariq.org/researchers/longfeng-zhang/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.